Literature DB >> 29853764

Treatment of Hair Loss in the Trichorhinophalangeal Syndrome.

Mi Soo Choi1, Myeong Jin Park1, Minkee Park1, Chan Hee Nam1, Seung Phil Hong1, Myung Hwa Kim1, Byung Cheol Park1.   

Abstract

Entities:  

Year:  2018        PMID: 29853764      PMCID: PMC5929967          DOI: 10.5021/ad.2018.30.3.382

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: Trichorhinophalangeal syndrome (TRPS) is a rare genetic condition that affects the hair, nose, and phalanges1. Patients with TRPS visit dermatologic clinics with complaint of alopecia. However, treatment option for alopecia in TRPS remains unclear. Herein, we report our experience of medical treatment and hair transplantation for alopecia of TRPS. A 17-year-old male patient complained of hair loss and slow growth rate of hair since his childhood. He had bulbous pear-shaped nose, long philtrum, thin upper vermilion boarder (Fig. 1A), and brachymetatarsia involving the 4th metatarsal of both feet. He had diffuse hair thinning and loss with regression of the frontotemporal hairline. The alopecia was M3V1 of basic and specific (BASP) classification (Fig. 1B). He had the typical triad of TRPS, including hair alterations, craniofacial changes, and skeletal abnormalities. We analyzed gene expression levels and identified differential expression of genes between the non-balding and balding scalp samples by RNA sequencing. Compared to non-balding scalp, the TRPS gene was down-regulated and we validated the result by the quantitative real-time polymerase chain reaction. For correcting his hair loss, we tried 5% minoxidil over 6 months. However, the alopecia progressed to C3V1 of BASP classification with more retarded growth (Fig. 1C). Then we tried finasteride 1 mg daily for 2 years, but alopecia was progressed to U1 of BASP classification (Fig. 2A). For cosmetic purpose, we transplanted hairs (1,300 follicular units) from occipital to the frontal and the mid-scalp area. Hair has grown up successfully over the 3 years of follow-up. Patient has been satisfied with the cosmetic result without complications (Fig. 2B).
Fig. 1

(A) Clinical photo of 17-year-old male with diffuse hair loss, bulbous pear-shaped nose, long philtrum, thin upper vermilion boarder, typical finding of trichorhinophalangeal syndrome. (B) Diffuse hair thinning and regression of frontotemporal hair line shown at the first visit. (C) Hair loss progressed to C3V1 of basic and specific classification and hair growth retardation was found despite of minoxidil treatment.

Fig. 2

(A) In spite of 2 years of treatment with finasteride (1 mg/d), alopecia has been worsened to U1 type in basic and specific classification and hairs has been thinner and thinner. (B) At 2 years after hair transplantation. Transplanted hair had grown successfully. The frontal hair line had been well maintained.

TRPS patients' diffuse alopecia varies, usually, from normal hair to complete baldness. Usually, frontotemporal hairline is receded and the scalp hairs grow slowly2. Marked decrease of hair diameter in scalp has been reported to be the main finding of TRPS3. The reduction of hair follicles is not the main trichologic finding, and individually thinning of hair is the main cause of the impression of sparse scalp hair in TRPS4. Therefore, the pathologic change and hair loss pattern in TRPS are very similar to those of male pattern baldness (MPB). TRPS1 protein is known to develop symptoms of TRPS. It has been reported TRPS1 is associated with the androgen pathway in prostatic cancer and breast cancer5. Therefore, we assumed conventional treatment for MPB including minoxidil and finasteride might be effective for hypotrichosis of TRPS, although the exact mechanisms and its treatment has not been elucidated clearly. However, topical minoxidil was never effective, and oral finasteride was also ineffective in preventing the progression of alopecia or inducing hair growth in TRPS. In severe TRPS, hair on the entire scalp could be affected, tend to be thinner4. However, the occipital scalp hairs of our patient had normal hair density and diameter based on trichoscopic and pathologic examinations. Finally, we tried to transplant hairs onto the alopetic area to improve his cosmesis. These transplanted hairs started to re-grow at 4 months after the operation. The survival rate was similar to the ordinary hair transplanted in MPB, and transplanted hair has grown up very well over the 3 years of follow-up. Thinning of implanted hair in the frontal and mid scalp did not occur in the present case.
  5 in total

1.  Trichorhinophalangeal syndrome.

Authors:  S Yáñez; I Hernández-Vicente; M Armijo
Journal:  Int J Dermatol       Date:  1992-10       Impact factor: 2.736

2.  The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.

Authors:  Glenn T G Chang; Mila Jhamai; Wytske M van Weerden; Guido Jenster; Albert O Brinkmann
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

3.  Trichorhinophalangeal syndrome type I: clinical and molecular characterization of 3 members of a family and 1 sporadic case.

Authors:  C S Seitz; H J Lüdecke; N Wagner; E B Bröcker; H Hamm
Journal:  Arch Dermatol       Date:  2001-11

4.  Trichorhinophalangeal syndrome with low expression of TRPS1 on epidermal and hair follicle epithelial cells.

Authors:  Taisuke Ito; Yutaka Shimomura; Muhammad Farooq; Noriko Suzuki; Jun-Ichi Sakabe; Yoshiki Tokura
Journal:  J Dermatol       Date:  2013-03-04       Impact factor: 4.005

5.  [Study of hair in type I tricho-rhino-phalangeal syndrome].

Authors:  B M Lalević-Vasić; M M Nikolić; D J Polić
Journal:  Ann Dermatol Venereol       Date:  1994       Impact factor: 0.777

  5 in total
  1 in total

1.  TRPS1 mutation detection in Chinese patients with Tricho-rhino-phalangeal syndrome and identification of four novel mutations.

Authors:  Chen Wang; Yufei Xu; Yanrong Qing; Ruen Yao; Niu Li; Xiumin Wang; Tingting Yu; Jian Wang
Journal:  Mol Genet Genomic Med       Date:  2020-08-10       Impact factor: 2.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.